Literature DB >> 8264643

Expression and function of TRK-B and BDNF in human neuroblastomas.

A Nakagawara1, C G Azar, N J Scavarda, G M Brodeur.   

Abstract

There is considerable interest in the role of the TRK family of neuotrophin receptors in regulating growth and differentiation in normal and neoplastic nerve cells. A neuroblastoma is a common pediatric tumor derived from the neural crest, and the majority of favorable neuroblastomas express a high level of TRK-A mRNA. However, little is known about the expression or function of TRK-B in these tumors. TRK-B encodes a tyrosine kinase that binds to brain-derived neuotrophic factor (BDNF), as well as neurotrophin-3 (NT-3) and NT-4/5. We have studied the N-myc-amplified human neuroblastoma cell line, SMS-KCN, which expresses both TRK-B and BDNF. Exogenous BDNF induces tyrosine phosphorylation of TRK-B as well as phosphorylation of phospholipase C-gamma 1, the extracellular signal-regulated kinases 1 and 2, and phosphatidylinositol-3 kinase. BDNF also induces expression of the immediate-early genes c-FOS and NGFI-A but not NGFI-B or NGFI-C. In addition, BDNF appears to promote cell survival and neurite outgrowth. SMS-KCN cells also express TRK-A, which is phosphorylated in response to nerve growth factor. However, the downstream TRK-A signaling is apparently defective. Finally, we determined that in a series of 74 primary neuroblastomas, 36% express TRK-B mRNA, 68% express BDNF mRNA, and 31% express both. Truncated TRK-B appears to be preferentially expressed in more-differentiated tumors (ganglioneuromas and ganglioneuroblastomas), whereas full-length TRK-B is expressed almost exclusively in immature neuroblastomas with N-myc amplification. Our findings suggest that in TRK-B-expressing human neuroblastomas, BDNF promotes survival and induces neurite outgrowth in an autocrine or paracrine manner. The BDNF/TRK-B pathway may be particularly important for growth and differentiation of neuroblastomas with N-myc amplification.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8264643      PMCID: PMC358424          DOI: 10.1128/mcb.14.1.759-767.1994

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  61 in total

1.  NGF and other growth factors induce an association between ERK1 and the NGF receptor, gp140prototrk.

Authors:  D M Loeb; H Tsao; M H Cobb; L A Greene
Journal:  Neuron       Date:  1992-12       Impact factor: 17.173

2.  Primary structure and biological activity of a novel human neurotrophic factor.

Authors:  A Rosenthal; D V Goeddel; T Nguyen; M Lewis; A Shih; G R Laramee; K Nikolics; J W Winslow
Journal:  Neuron       Date:  1990-05       Impact factor: 17.173

3.  Identification and characterization of a novel member of the nerve growth factor/brain-derived neurotrophic factor family.

Authors:  A Hohn; J Leibrock; K Bailey; Y A Barde
Journal:  Nature       Date:  1990-03-22       Impact factor: 49.962

4.  A nerve growth factor-induced gene encodes a possible transcriptional regulatory factor.

Authors:  J Milbrandt
Journal:  Science       Date:  1987-11-06       Impact factor: 47.728

Review 5.  Physiology of nerve growth factor.

Authors:  H Thoenen; Y A Barde
Journal:  Physiol Rev       Date:  1980-10       Impact factor: 37.312

6.  Inverse correlation between N-myc amplification and catecholamine metabolism in children with advanced neuroblastoma.

Authors:  A Nakagawara; K Ikeda; K Higashi; T Sasazuki
Journal:  Surgery       Date:  1990-01       Impact factor: 3.982

7.  Molecular cloning and neurotrophic activities of a protein with structural similarities to nerve growth factor: developmental and topographical expression in the brain.

Authors:  P Ernfors; C F Ibáñez; T Ebendal; L Olson; H Persson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

8.  Novel roles for neurotrophins are suggested by BDNF and NT-3 mRNA expression in developing neurons.

Authors:  L C Schecterson; M Bothwell
Journal:  Neuron       Date:  1992-09       Impact factor: 17.173

9.  Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma.

Authors:  A Nakagawara; M Arima-Nakagawara; N J Scavarda; C G Azar; A B Cantor; G M Brodeur
Journal:  N Engl J Med       Date:  1993-03-25       Impact factor: 91.245

10.  K252a is a selective inhibitor of the tyrosine protein kinase activity of the trk family of oncogenes and neurotrophin receptors.

Authors:  P Tapley; F Lamballe; M Barbacid
Journal:  Oncogene       Date:  1992-02       Impact factor: 9.867

View more
  119 in total

Review 1.  Diagnosis and classification of the small round-cell tumors of childhood.

Authors:  S L Cohn
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

2.  Farnesyltransferase inhibitor FTI-277 prevents autocrine growth stimulation of neuroblastoma by BDNF.

Authors:  Rainer Girgert; Josefa Wittrock; Sabine Pfister; Paul Schweizer
Journal:  J Cancer Res Clin Oncol       Date:  2003-04-17       Impact factor: 4.553

3.  TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.

Authors:  Jamie L Croucher; Radhika Iyer; Nanxin Li; Valentina Molteni; Jon Loren; W Perry Gordon; Tove Tuntland; Bo Liu; Garrett M Brodeur
Journal:  Cancer Chemother Pharmacol       Date:  2014-11-14       Impact factor: 3.333

Review 4.  Neuroblastoma as a neurobiological disease.

Authors:  N F Schor
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

5.  AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts.

Authors:  Radhika Iyer; Carly R Varela; Jane E Minturn; Ruth Ho; Anisha M Simpson; Jennifer E Light; Audrey E Evans; Huaqing Zhao; Kenneth Thress; Jeffrey L Brown; Garrett M Brodeur
Journal:  Cancer Chemother Pharmacol       Date:  2012-05-24       Impact factor: 3.333

6.  Pharmacological characterization of six trkB antibodies reveals a novel class of functional agents for the study of the BDNF receptor.

Authors:  M Cazorla; J M Arrang; J Prémont
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

7.  Predicting neuroblastoma using developmental signals and a logic-based model.

Authors:  Jennifer C Kasemeier-Kulesa; Santiago Schnell; Thomas Woolley; Jennifer A Spengler; Jason A Morrison; Mary C McKinney; Irina Pushel; Lauren A Wolfe; Paul M Kulesa
Journal:  Biophys Chem       Date:  2018-04-30       Impact factor: 2.352

Review 8.  Therapeutic targets for neuroblastomas.

Authors:  Garrett M Brodeur; Radhika Iyer; Jamie L Croucher; Tiangang Zhuang; Mayumi Higashi; Venkatadri Kolla
Journal:  Expert Opin Ther Targets       Date:  2014-01-06       Impact factor: 6.902

9.  Neuroblastoma phox2b variants stimulate proliferation and dedifferentiation of immature sympathetic neurons.

Authors:  Tobias Reiff; Konstantina Tsarovina; Afsaneh Majdazari; Mirko Schmidt; Isabel del Pino; Hermann Rohrer
Journal:  J Neurosci       Date:  2010-01-20       Impact factor: 6.167

10.  Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors.

Authors:  Samir D Undevia; Nicholas J Vogelzang; Ann M Mauer; Linda Janisch; Sridhar Mani; Mark J Ratain
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.